GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
NEW YORK, June 20, 2025 /PRNewswire/ -- Players such as GE HealthCare, Siemens Healthineers, Philips,…
The JMIR Publications portfolio of journals now includes 21 journals with a Journal Impact Factor, with…
PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today…
NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of…
PITTSBURGH, June 20, 2025 /PRNewswire/ -- Catalyst MedTech, a national leader in nuclear medicine and…
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025…